A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From <i>Clostridioides difficile</i> Infection Following the IDSA 2021 Clinical Guideline Update: <i>Clostridioides difficile</i> Infection.

ABSTRACT:

Background

The 2021 update to the Infectious Diseases Society of America Clostridioides difficile infection (CDI) guidelines recommended fidaxomicin as the preferred treatment over vancomycin for patients with initial and recurrent CDI. Few studies have examined how treatment patterns and clinical outcomes of hospitalized CDI patients changed after the postguideline update or contemporary real-world outcomes of fidaxomicin vs vancomycin.

Methods

This retrospective, observational study used the PINC AI Healthcare Database on adult patients who received CDI treatment between 1/2020 and 6/2021 (pre period) and between 10/2021 and 9/2022 (post period). We examined treatment patterns of fidaxomicin, vancomycin, and metronidazole, as well as clinical and health care resourc

SUBMITTER: Dubberke ER 

PROVIDER: S-EPMC11443340 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature